Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma.

Shi, Zheng; Wei, Jingwen; Xu, Manyi; Song, Zhengbo

Shi, Zheng; Wei, Jingwen; Xu, Manyi; Song, Zhengbo.

Afiliação

Shi Z; Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Wei J; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China.
Xu M; Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Song Z; Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China.

J Thorac Dis ; 15(8): 4172-4181, 2023 Aug 31.

Article em En | MEDLINE | ID: mdl-37691658

Palavras-chave

Efficacy; immune checkpoint inhibitors (ICIs); immune-related adverse events (irAEs); lung large-cell neuroendocrine carcinoma (L-LCNEC); safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Thorac Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google